TARCEVA clinical registry;Klinický registr TARCEVA

Klinicka Onkologie

Volumn 23, Issue 5, 2010, Pages 361-363

  Skřičková, Jana ^a   Pesek M ^b   Zatloukal, P ^c   Kolek, V ^d   Salajka, F ^e   Koubkova L ^f   Krejci J ^b   Tomiskova M ^a   Grygarkova Y ^d   Havel, L ^c   Hrnciarik M ^e   Skalova B ^f   Sticha M ^g  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIVERSITY HOSPITAL BULOVKA   (Czech Republic)

^d UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^e UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^f UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^g MASARYK UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ERLOTINIB;

ARTICLE; HUMAN;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; REGISTRIES;

EID: 78149347277     PISSN: 0862495X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999, 82(2-3): 241-250.
2. Salomon DS, Brandt R, Ciardiello F et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19(3): 183-232.
3. Souhrn údajů o přípravku Tarceva, datum revize textu 1. 7. 2010.
4. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353(2): 123-132.